Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

2.

Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.

Logan YT, Belgeri MT.

Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. Review.

PMID:
16129387
3.

Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.

Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J; Proscar Long-Term Efficacy and Safety Study Group.

J Urol. 2004 Mar;171(3):1194-8.

PMID:
14767299
4.

Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study.

Albertsen PC, Pellissier JM, Lowe FC, Girman CJ, Roehrborn CG.

Clin Ther. 1999 Jun;21(6):1006-24.

PMID:
10440624
5.

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia.

Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P.

Urology. 1997 Jun;49(6):839-45.

PMID:
9187688
6.

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coffield S, Saltzman B, Resnick M, Cook TJ, Waldstreicher J.

Urology. 1999 Mar;53(3):473-80.

PMID:
10096369
7.
8.

5alpha-reductase inhibitors: what role should they play?

Kaplan SA.

Urology. 2001 Dec;58(6 Suppl 1):65-70; discussion 70. Review.

PMID:
11750255
9.

Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group.

Roehrborn CG, Bruskewitz R, Nickel GC, Glickman S, Cox C, Anderson R, Kandzari S, Herlihy R, Kornitzer G, Brown BT, Holtgrewe HL, Taylor A, Wang D, Waldstreicher J.

Eur Urol. 2000 May;37(5):528-36.

PMID:
10765090
13.

Long-term results of medical treatment in benign prostatic hyperplasia.

Kim CI, Chang HS, Kim BK, Park CH.

Urology. 2006 Nov;68(5):1015-9. Epub 2006 Nov 7.

PMID:
17095071
14.

5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.

Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M.

Eur Urol. 2004 May;45(5):620-6; discussion 626-7.

PMID:
15082205
15.

Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.

Kaplan SA, Holtgrewe HL, Bruskewitz R, Saltzman B, Mobley D, Narayan P, Lund RH, Weiner S, Wells G, Cook TJ, Meehan A, Waldstreicher J; Proscar Long-Term Efficacy and Safety Study Group.

Urology. 2001 Jun;57(6):1073-7.

PMID:
11377309
16.

Finasteride for benign prostatic hyperplasia.

Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ.

Cochrane Database Syst Rev. 2010 Oct 6;(10):CD006015. doi: 10.1002/14651858.CD006015.pub3. Review.

PMID:
20927745
17.

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group.

Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R, Reddy P, Rosenberg S, Sussman D, White C, Lee M, Pappas F, Waldstreicher J.

Urology. 2000 Oct 1;56(4):610-6.

PMID:
11018616
18.
20.

Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.

Roehrborn CG, McConnell JD, Saltzman B, Bergner D, Gray T, Narayan P, Cook TJ, Johnson-Levonas AO, Quezada WA, Waldstreicher J; PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

Eur Urol. 2002 Jul;42(1):1-6.

PMID:
12121721

Supplemental Content

Support Center